These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9951955)

  • 1. Ibandronate.
    Dooley M; Balfour JA
    Drugs; 1999 Jan; 57(1):101-8; discussion 109-10. PubMed ID: 9951955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone.
    Coukell AJ; Markham A
    Drugs Aging; 1998 Feb; 12(2):149-68. PubMed ID: 9509293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
    Plosker GL; Goa KL
    Drugs; 1994 Jun; 47(6):945-82. PubMed ID: 7521833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibandronate in oncology.
    Burckhardt P
    Cancer; 1997 Oct; 80(8 Suppl):1696-8. PubMed ID: 9362439
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study.
    Ravn P; Clemmesen B; Riis BJ; Christiansen C
    Bone; 1996 Nov; 19(5):527-33. PubMed ID: 8922653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
    Guay DR
    Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.
    Schimmer RC; Bauss F
    Clin Ther; 2003 Jan; 25(1):19-34. PubMed ID: 12637110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.
    Thiébaud D; Burckhardt P; Kriegbaum H; Huss H; Mulder H; Juttmann JR; Schöter KH
    Am J Med; 1997 Oct; 103(4):298-307. PubMed ID: 9382122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P
    Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
    Fitton A; McTavish D
    Drugs; 1991 Feb; 41(2):289-318. PubMed ID: 1709854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous ibandronate: in the treatment of osteoporosis.
    Croom KF; Scott LJ
    Drugs; 2006; 66(12):1593-601; discussion 1602-3. PubMed ID: 16956306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys.
    Smith SY; Recker RR; Hannan M; Müller R; Bauss F
    Bone; 2003 Jan; 32(1):45-55. PubMed ID: 12584035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
    Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG
    Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibandronate treatment in Paget's disease of bone.
    Grauer A; Heichel S; Knaus J; Dosch E; Ziegler R
    Bone; 1999 May; 24(5 Suppl):87S-89S. PubMed ID: 10321936
    [No Abstract]   [Full Text] [Related]  

  • 15. Risedronate: a new oral bisphosphonate.
    Umland EM; Boyce EG
    Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates: an overview with special reference to alendronate.
    Vasikaran SD
    Ann Clin Biochem; 2001 Nov; 38(Pt 6):608-23. PubMed ID: 11732644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease.
    Douglas DL; Duckworth T; Russell RG; Kanis JA; Preston CJ; Preston FE; Prenton MA; Woodhead JS
    Lancet; 1980 May; 1(8177):1043-7. PubMed ID: 6103389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonate therapy.
    Licata AA
    Am J Med Sci; 1997 Jan; 313(1):17-22. PubMed ID: 9001162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of the new bisphosphonate ibandronate in the management of bone metastasis following rapid infusion.
    Syrigos KN; Michalaki V; Mitromaras A; Pliarchopoulou F; Katirtzoglou N; Antonaki E; Roussou P
    In Vivo; 2002; 16(5):361-3. PubMed ID: 12494878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New bisphosphonates in the treatment of bone diseases.
    Gatti D; Adami S
    Drugs Aging; 1999 Oct; 15(4):285-96. PubMed ID: 10582775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.